Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Jul 31;1:2055217315596994. doi: 10.1177/2055217315596994

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2015

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page(https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 1. — Patients developing lymphopenia remain lymphopenic throughout DMF treatment. Baseline ALCs (a) include nine patients on fingolimod. Longitudinal ALCs were monitored for patients developing grade 1 (b), grade 2 (c) and grade 3 (d) lymphopenia. Nine lymphopenic patients discontinued DMF; subsequent ALC recovery is plotted (e). Two patients who transitioned to fingolimod therapy are not shown. Dotted lines represent ALC 1000, 800, and 500, the cutoff values for grade 1, 2, and 3 lymphopenia, respectively. DMF: dimethyl fumarate; ALC: absolute lymphocyte count.